- In SURMOUNT-5 (NEJM, 2025), the only published head-to-head trial, tirzepatide produced an average 20.2% body weight loss against 13.7% for semaglutide at 72 weeks.
- Retatrutide, an investigational triple agonist, averaged 28.3% weight loss at 80 weeks on the highest dose in the TRIUMPH-1 Phase 3 trial. It is not FDA-approved and has no lawful consumer source.
- A 2026 Nature study of 27,885 people linked GLP1R variants to modestly greater average weight loss and GIPR variants to nausea on tirzepatide.
- A 2026 Genome Medicine study linked PAM gene variants, carried by about 10% of people, to lower rates of reaching blood sugar targets on GLP-1 drugs.
- These are group-level associations. None has been shown to improve outcomes when used to choose a drug, and prescribing decisions belong to the prescriber.
Semaglutide and tirzepatide are FDA-approved prescription drugs; retatrutide is still investigational. This page compares what the clinical trials of the three found and what the 2026 genetics research adds. It reports research. Decisions about these drugs, including whether to start, stop or switch, belong to a prescriber.
Average body weight loss at 72 weeks for tirzepatide versus semaglutide in SURMOUNT-5, the first published head-to-head randomized trial (New England Journal of Medicine, 2025). The difference was consistent across the trial's prespecified subgroups.
All three drugs act on gut-hormone receptors, and each adds one. Semaglutide (Ozempic, Wegovy) activates the GLP-1 receptor, reducing appetite and slowing stomach emptying. Tirzepatide (Mounjaro, Zepbound) adds the GIP receptor. Retatrutide adds a third, the glucagon receptor, which is thought to raise energy expenditure.
Think of each receptor as a channel carrying a "you're full" or "burn more" message. Semaglutide uses one channel, tirzepatide two, retatrutide three. In the trials so far, more channels went with more average weight loss.
Tirzepatide vs semaglutide: the one head-to-head trial
For years the comparison relied on separate trials with different populations. SURMOUNT-5 was the first direct randomized comparison in adults with obesity or overweight.
Tirzepatide resulted in significantly greater weight reduction than semaglutide, with a mean body-weight loss of 20.2% versus 13.7% at 72 weeks in adults with obesity or overweight. The between-group difference of 6.5 percentage points was consistent across all prespecified subgroups.
SURMOUNT-5, New England Journal of Medicine, 2025
Researchers attribute part of the gap to tirzepatide's GIP receptor activity, which affects insulin secretion and fat-cell metabolism and may make it easier to tolerate higher doses.
The late-responder finding
A post-hoc analysis of SURMOUNT-1, published in Diabetes, Obesity and Metabolism in 2025, looked at people on tirzepatide who had lost under 5% of their weight by week 12. That group made up 18% of participants. Ninety percent of them passed 5% by week 72, with a median crossing around week 25 and a mean final loss of 11%. Whether the same pattern holds for semaglutide has not been published. What to make of an early slow response is a question for the prescriber.
Retatrutide: the Phase 3 results
Retatrutide is an investigational drug. It is not FDA-approved, there is no lawful consumer source in the US, and products sold online under its name are not the trial drug and have no verified content.
Average weight loss at 80 weeks on the highest retatrutide dose in the TRIUMPH-1 Phase 3 trial (NEJM, May 2026). In the extension, the figure at 104 weeks was 30.3%.
TRIUMPH-1 enrolled 2,339 adults. On the highest dose, average weight loss was 28.3% at 80 weeks and 30.3% at 104 weeks in the extension; 45.3% of participants on that dose lost 30% or more, and 65.3% moved out of the obese BMI category. A body composition substudy in Lancet Diabetes and Endocrinology (2025) reported that roughly 75 to 80% of the weight lost was fat mass, a ratio similar to semaglutide and tirzepatide. No published trial has compared retatrutide directly with tirzepatide. The retatrutide research summary covers the trials in more detail.
| Drug | Receptors | Average weight loss | Source | Status (2026) |
|---|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | GLP-1 | 13.7% at 72 weeks | SURMOUNT-5, NEJM 2025 | FDA-approved |
| Tirzepatide (Mounjaro, Zepbound) | GLP-1 + GIP | 20.2% at 72 weeks | SURMOUNT-5, NEJM 2025 | FDA-approved |
| Retatrutide | GLP-1 + GIP + glucagon | 28.3% at 80 weeks (highest dose) | TRIUMPH-1, NEJM May 2026 | Investigational, not approved |
What the 2026 genetics studies found
Two 2026 studies added genetic data to this comparison. Both describe associations across groups of people.
A 2026 Nature study from the 23andMe Research Institute analysed 27,885 people who had taken semaglutide or tirzepatide. Each copy of the GLP1R rs10305420 effect allele was associated with about 0.76 kg of additional weight loss, reaching genome-wide significance. That is a small difference against the average weight loss in the trials, and people with either genotype lost weight on average.
The same study linked GIPR variants to nausea and vomiting on tirzepatide and not on semaglutide. Because tirzepatide acts on the GIP receptor and semaglutide does not, the finding fits the pharmacology.
A Stanford and ETH Zurich study in Genome Medicine (April 2026) found that PAM variants carried by about 10% of people, which impair the enzymatic activation of GLP-1, were associated with lower rates of reaching HbA1c targets at 6 months on GLP-1 drugs: 11.5% for p.S539W carriers against about 25% for non-carriers.
How to read those findings
These are real associations from large studies. They do not tell any one person how they will respond, and no study has tested whether choosing between these drugs by genotype improves outcomes. Genotype-guided prescribing for GLP-1 drugs is not current standard practice. A DNA report can show which versions of these genes you carry and what the research has linked them to; it is context for a conversation with a prescriber, not a recommendation. The semaglutide genetics article covers the variants in more detail.
Clear trial differences between the drugs, and modest genetic associations.
Tirzepatide produced more average weight loss than semaglutide in the one head-to-head trial, and retatrutide produced more again in Phase 3 but is not approved and has no lawful consumer source. The 2026 genetics studies found real but modest group-level associations that have not been shown to guide drug choice. Prescription decisions belong to the prescriber.

Watch
What clinicians and researchers say about Semaglutide
1 hr 30 minPeptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex TatemThe Diary of a CEO · PodcastBPC-157TB-500MOTS-c
24 minI'm a Pathologist. Ozempic & Mounjaro Aren't Actually Weight Loss Drugs.Amin Hedayat · ClinicianSemaglutideTirzepatide
28 minI’m a Pathologist: The "Biological Cost" of Ozempic and Mounjaro.Amin Hedayat · ClinicianSemaglutideTirzepatideFrequently asked questions
Did tirzepatide produce more weight loss than semaglutide?
In SURMOUNT-5 (NEJM, 2025), the only published head-to-head randomized trial, tirzepatide produced an average 20.2% body weight loss against 13.7% for semaglutide at 72 weeks, a difference consistent across the trial's subgroups. Choosing between them is a decision for a prescriber.
What is retatrutide and is it approved?
Retatrutide is an investigational triple GIP, GLP-1 and glucagon receptor agonist. In the TRIUMPH-1 Phase 3 trial it produced 28.3% average weight loss at 80 weeks on the highest dose. It is not FDA-approved, there is no lawful consumer source in the US, and products sold online under its name are not the trial drug.
Can my DNA tell me which GLP-1 drug will work better for me?
Not in a way that has been shown to improve outcomes. A 2026 Nature study of 27,885 people linked GLP1R variants to modestly greater average weight loss and GIPR variants to nausea on tirzepatide. These are group-level associations; no study has tested genotype-guided choice between these drugs.
What is the PAM gene finding?
PAM is an enzyme that activates GLP-1 through amidation. A 2026 Genome Medicine study found that PAM variants carried by about 10% of people were associated with lower rates of reaching HbA1c targets at 6 months on GLP-1 drugs (11.5% for p.S539W carriers against about 25% for non-carriers).
What did the SURMOUNT-1 late-responder analysis find?
A 2025 post-hoc analysis found that 18% of people on tirzepatide had lost under 5% of their weight at week 12, and 90% of that group passed 5% by week 72, with a mean final loss of 11%. What an early slow response means for an individual is a question for the prescriber.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.